Wugen Presents Data Supporting Clinical Development of WU-NK-101 for Relapsed / Refractory AML at th
– Genetic tumor microenvironment (TME) signature identified as highly predictive of duration of response to cytokine-induced memory-like (CIML) NK cell therapy –– WU-NK-101 exhibited enhanced anti-tumor activity, robust bone marrow trafficking, and metabolic flexibility –– Phase 1 clinical study of WU-NK-101 for off...
Source: pharmiweb.com